IL17RB expression is associated with malignant cancer behaviors and poor prognosis in oral cancer

Abstract

ObjectivesPreviously, we demonstrated that IL17RB plays an essential role in lung cancer progression. This study aimed to determine whether IL17RB correlates with oral cancer and promotes oral cancer progression.Subjects and MethodsIL17RB expression in oral cancer tissues and normal tissues was determined by immunohistochemistry staining, while the association of IL17RB expression with the clinicopathological characteristics of oral squamous cell carcinoma (OSCC) patients was analyzed and its correlation with progression‐free survival and response to radiotherapy and chemotherapy in OSCC patients was also explored. Western blotting was performed to investigate the expression of IL17RB in various OSCC cell lines; moreover, transwell assay was performed to evaluate the effect of IL17RB expression on cell migration ability.ResultsIn this study, we found that IL17RB was expressed higher in OSCC tissues compared to normal oral mucosa tissues and its expression was positively correlated with tumor size, lymph node metastasis, advanced cancer stage, and poor prognosis. In vitro study showed that IL17RB expression in OSCC cell lines as determined by Western blotting, was positively correlated with their migration ability.ConclusionClinical and in vitro studies suggest that IL17RB might serve as an independent risk factor and a therapeutic target for oral cancer.

Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity

“…On the other hand, IL-17RB, being the coreceptor for IL-25, has also been reported to be associated with poor prognosis in malignancies such as oral cancer. 39 However, we did not observe enhanced survival probability for colorectal or breast cancer patients with lower IL-17RB expression in CD4 T cells ( figure 5D ). Altogether, retrospective patient survival data suggest that patients with cancer could benefit from IL-17RA neutralization but not IL-17RB neutralization.…”